Novo Nordisk is a large-cap pharmaceutical company with exceptional 71% return on equity, 37% net margins, and 24% revenue growth, but a confirmed long-term downtrend, elevated put/call ratio of 4.95, and consecutive earnings misses create near-term caution.
Thesis pillars
- Elite Margins And Returns→Stable
- Earnings Miss Streak Deceleration→Stable
- Confirmed Long Term Downtrend↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Novo Nordisk A/S (NVO) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - General
Hold if already holding. Not a fresh buy at $40.19, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides... Read more
Hold if already holding. Not a fresh buy at $40.19, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: Death cross but MACD improving, RSI 64. Downgraded from BUY WAIT — price $40.19 vs the analyst target $39.38: -2.0% upside; No upside left. Score 5.6/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, news boost earnings 0.90, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.
Recent developments
updated Nov 3, 2026Recent Developments — Novo Nordisk A/S
Latest news
- NEWS Novo Nordisk A/S - share repurchase programme - www.marketscreener.com — www.marketscreener.com Nov 3, 2026 positive
- NEWS Novo Nordisk Loses Court Bid Against Eli Lilly’s Weight-Loss Drug Ads — Judge Says Sales Impact Was Negli - Benzinga — Benzinga Oct 28, 2026 negative
- NEWS Court decision leaves Novo Nordisk stock price vulnerable as sellers dominate - Traders Union — Traders Union Oct 28, 2026 negative
- NEWS Novo Nordisk Vs. Eli Lilly Q3 Preview: I'd (Now) Buy Both, But Lilly Is My Top Pick (NVO) - Seeking Alpha — Seeking Alpha Oct 27, 2026 positive
- NEWS NVO Stock Price and Chart — BX:NVO - TradingView — TradingView Oct 27, 2026 neutral
Latest item Nov 3, 2026 · Generated 2026-11-04T11:49:37Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $40.19, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak growth. Chart setup: Death cross but MACD improving, RSI 64. Downgraded from BUY WAIT — price $40.19 vs the analyst target $39.38: -2.0% upside; No upside left. Analyst target $39.38 reached (−2.0%), stop $37.88 (−6.1%), A.R:R -0.3:1. Score 5.6/10, moderate confidence.
Analyst target $39.38 reached (−2.0% from $40.19); no take-profit level is published. Analyst target $39.38 reached (−2.0%), stop $37.88 (−6.1%), A.R:R -0.3:1. Stop-loss: $37.88.
Analyst target reached - limited upside remaining; Weak growth; Below 200-MA, MA slope -4.0%/30d (confirmed downtrend).
Novo Nordisk A/S trades at a P/E of 9.9 (forward 11.7). TrendMatrix value score: 7.0/10. Verdict: Hold.
36 analysts rate NVO, with a consensus score of 3.2/5. 12 analysts publish price targets averaging $45.
What does Novo Nordisk A/S do?Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and...
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.